Anzeige
Mehr »
Login
Freitag, 18.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
5 Millionen Unzen und steigend: NexGold Mining's unerschlossene Goldstraße
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 157713 | ISIN: GB0002892528 | Ticker-Symbol: XE4
Frankfurt
17.10.24
08:04 Uhr
0,001 Euro
0,000
0,00 %
1-Jahres-Chart
SURFACE TRANSFORMS PLC Chart 1 Jahr
5-Tage-Chart
SURFACE TRANSFORMS PLC 5-Tage-Chart
Dow Jones News
374 Leser
Artikel bewerten:
(2)

Surface Transforms PLC: Pre-Close Trading and Operational Update

DJ Surface Transforms PLC: Pre-Close Trading and Operational Update

Surface Transforms PLC (-) 
Surface Transforms PLC: Pre-Close Trading and Operational Update 
19-Jul-2024 / 12:25 CET/CEST 
=---------------------------------------------------------------------------------------------------------------------- 
 
The information contained within this announcement is deemed by the Company to constitute inside information stipulated 
under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union 
 (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside 
information is now considered to be in the public domain. 
 
19 July 2024 
 
 
Surface Transforms plc 
("Surface Transforms" or "the Company") 
 
Pre-Close trading and operational update 
 
Surface Transforms (AIM:SCE), manufacturers of carbon fibre reinforced ceramic automotive brake discs, provides the 
following pre-close trading and operations update for the six months to 30 June 2024 ("H1 24"). 
 
Sales 
 
Sales guidance for 2024 remains in line with market estimates - GBP17.5m - as current output levels are delivering to our 
revised customer needs. 
 
We are pleased to report that production of discs has doubled in the four weeks ended 12 July 2024 from the average 
levels achieved over the previous 5 months, and importantly, on a consistent daily basis. 
 
Total sales for H1 24 were GBP4.6m, including the impact of no pre-production engineering revenues due to the revision to 
the Company's revenue recognition policy. We anticipate recognising GBP1.7m in engineering sales during H2 24. 
 
We will continue to grow, and our planned rate of growth is not without risk, but the Board believes that we also 
remain on track to deliver market estimates for 2025 including GBP28.0m sales, positive EBITDA and operational cash 
generation. 
 
Production 
 
Over the last four weeks, we have consistently been achieving record daily and weekly production levels that enable us 
to meet our requisite run rates on output to meet full year estimates. 
 
As previously announced, Q2 was impacted by the following production challenges: 
 
?? Supply chain difficulties in April and May caused by working capital constraints. These problems were progressively 
resolved in full during June following the recent fund raising. 
 
 
?? Yields have been lower than expected but have held steady at 75%. We have a clear pathway to further improvements 
and expect to achieve the previously guided 86% yield in Q4 2024. 
 
Because of these challenges, both tooling and R&D costs were approximately GBP2m higher in H1 24 than forecast. Whilst 
tooling costs are now reducing, the cost of improving yields will continue to be higher than previously forecast for 
the full year. 
 
Cash Position 
 
Cash as at 30 June 2024 was GBP5.0m. While we expect this to reduce towards the year end, no further funding is required. 
 
Further Updates 
 
Management will present a more detailed update following the AGM on Tuesday 23 July. We expect to publish the interim 
half year accounts in September 2024. 
 
Kevin Johnson (CEO) said "The recent significant increase in daily output levels, over several weeks, is most 
encouraging both in terms of its consistency and recent output levels. Capacity constraint is diminishing as a 
production impediment, thanks to the reduction of the single points of failure problem. We acknowledge that production 
yields, whilst improving, are still below plan. However the issues are understood, we expect to overcome them, and we 
are now building these further improvements from this higher baseline 
 
We look forward to meeting shareholders at next week's AGM to provide a fuller update" 
 
For enquiries, please contact: 
Surface Transforms plc              +44 151 356 2141 
David Bundred, Chairman 
Kevin Johnson CEO 
 
Isabelle Maddock CFO 
Zeus (Nominated Adviser and Joint Broker)    +44 203 829 5000 
David Foreman / James Edis (Investment Banking) 
Dominic King (Corporate Broking) 
Cavendish Capital Markets Ltd (Joint Broker)   +44 20 7220 0500 
Ed Frisby / Abigail Kelly (Corporate Finance) 
 
Andrew Burdis / Harriet Ward (ECM) 

About Surface Transforms

Surface Transforms plc. (AIM:SCE) develops and produces carbon-ceramic material automotive brake discs. The Company is the UK's only manufacturer of carbon-ceramic brake discs, and only one of two mainstream carbon ceramic brake disc companies in the world, serving customers that include major OEMs in the global automotive markets.

The Company utilises its proprietary next generation Carbon Ceramic Technology to create lightweight brake discs for high-performance road and track applications for both internal combustion engine cars and electric vehicles. While competitor carbon-ceramic brake discs use discontinuous chopped carbon fibre, Surface Transforms interweaves continuous carbon fibre to form a 3D matrix, producing a stronger and more durable product with improved heat conductivity compared to competitor products; this reduces the brake system operating temperature, resulting in lighter and longer life components with superior brake performance. These benefits are in addition to the benefits of all carbon-ceramic brake discs vs. iron brake discs: weight savings of up to 70%, longer product life, consistent performance, reduced brake pad dust and corrosion free.

The Company holds the London Stock Exchange's Green Economy Mark.

For additional information please visit www.surfacetransforms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Category Code: TST 
TIDM:     - 
LEI Code:   213800GQHNJPE5O8XO79 
Sequence No.: 335383 
EQS News ID:  1950187 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1950187&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

July 19, 2024 06:26 ET (10:26 GMT)

© 2024 Dow Jones News
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.